MEDICLINIC INTERNATIONAL PLC - Mediclinic International plc appoints Dame Inga Beale as independent non-executive director and chair designate

Mediclinic International plc appoints Dame Inga Beale as independent non-executive director and chair designate

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic” or “the Company” or “the Group”)

27 March 2020

MEDICLINIC INTERNATIONAL PLC APPOINTS DAME INGA BEALE AS INDEPENDENT
NON-EXECUTIVE DIRECTOR AND CHAIR DESIGNATE

Mediclinic, a leading international private healthcare services group, announces the
appointment of Dame Inga Beale as an independent non-executive director and Chair
Designate with effect from 26 March 2020. Following a handover period, Dame Inga will
succeed Dr Edwin Hertzog as Chair upon his retirement at the conclusion of the Company’s
annual general meeting on 22 July 2020.

Dame Inga has extensive business management and leadership experience, and was
appointed in 2014 as the first female Chief Executive Officer of Lloyd's of London, the insurance
and reinsurance market, a position which she held until 2018. She currently serves as an
independent member of the global strategy board of Clyde & Co LLP and as an independent
non-executive director on the boards of Crawford & Company and London First. In addition,
Dame Inga serves on the London Mayor’s Business Advisory Board. She is also Patron of
Insuring Women’s Futures and Chair of the UK HIV Commission. During her executive career,
she held various senior leadership positions in Switzerland and internationally across the
insurance sector, including at Converium, Zurich Insurance Group, Canopius and GE Insurance
Solutions.

Dame Inga is a Chartered Insurer and studied economics and accounting. In 2017, she was
appointed Dame Commander of the Order of the British Empire for services to the UK economy.

Dame Inga has also been appointed as a member of the Nomination Committee with effect
from 26 March 2020.

Dr Edwin Hertzog, Chair of Mediclinic International, commented:
“The Board is delighted to welcome Dame Inga as an independent non-executive director and
Chair Designate of the Company. She has a clear understanding of our strong culture and
values and will also align readily with our business. Core to these matters are our stakeholder
commitment to deliver sustainable high-quality healthcare services and our purpose to enhance
the quality of life. Dame Inga will expertly lead the Board in pursuit of these objectives including
the challenge if the COVID-19 pandemic continues to spread globally.”

Alan Grieve, the Company’s Senior Independent Director, who led the planned
succession process, commented:
“I am very pleased with the outcome of the thorough and independent process conducted to
identify a successor to Dr Hertzog. Dame Inga will contribute a wealth of business experience,
both as a leader and role model. During her tenure at Lloyd’s of London she initiated large-
scale digital and cultural transformation programmes and led its expansion into Dubai, China
and India. Dame Inga also played a critical role in advancing diversity and inclusion initiatives
across Lloyd’s and the international insurance sector.”

Dame Inga Beale commented:
“I am very pleased to be joining Mediclinic International, an organisation that puts patients at
the heart of its business. The Group has a clear strategy and exciting long-term outlook under
the leadership of Dr Ronnie Van der Merwe and his executive team. I look forward to working
with the Board, the executive team and Mediclinic’s various stakeholders as the Company
builds on the market-leading positions of its three divisions and adapts to the changing global
healthcare environment.”

This announcement is made in accordance with the requirement of LR 9.6.11. There are no
further details that are required to be disclosed under LR 9.6.13.

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United
Arab Emirates.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.

As at 1 March 2020, Mediclinic comprised 77 hospitals, five sub-acute hospitals, 14 day case
clinics and 22 outpatient clinics. Hirslanden operated 17 hospitals, two day case clinics and
three outpatient clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern
Africa operations included 53 hospitals (three of which in Namibia), five sub-acute hospitals and
10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8
500 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics
and 19 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United
Kingdom, with secondary listings on the JSE Ltd ("JSE") in South Africa and the Namibian
Stock Exchange ("NSX") in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 27-03-2020 09:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.